It is suggested that NR can enhance mitochondrial function via the SIRT1 and SIRT3 PGC-1α pathway and could also delay the translocation of mutant Htt into the nucleus, demonstrating that it is a potential pharmacologic agent for treating HD [123]. This evidence concerns the gene HTT and Huntington disease.